359 related articles for article (PubMed ID: 19271220)
1. Economic aspects of bladder cancer: what are the benefits and costs?
Sievert KD; Amend B; Nagele U; Schilling D; Bedke J; Horstmann M; Hennenlotter J; Kruck S; Stenzl A
World J Urol; 2009 Jun; 27(3):295-300. PubMed ID: 19271220
[TBL] [Abstract][Full Text] [Related]
2. [Cost-effectiveness of transurethral resection of the bladder with blue light in patients with non muscle invasive bladder cancer in France].
Rouprêt M; Malavaud B; Molinier L; Leleu H; Blachier M; Marteau F
Prog Urol; 2015 Apr; 25(5):256-64. PubMed ID: 25605343
[TBL] [Abstract][Full Text] [Related]
3. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.
Rink M; Babjuk M; Catto JW; Jichlinski P; Shariat SF; Stenzl A; Stepp H; Zaak D; Witjes JA
Eur Urol; 2013 Oct; 64(4):624-38. PubMed ID: 23906669
[TBL] [Abstract][Full Text] [Related]
4. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT.
Heer R; Lewis R; Duncan A; Penegar S; Vadiveloo T; Clark E; Yu G; Mariappan P; Cresswell J; McGrath J; N'Dow J; Nabi G; Mostafid H; Kelly J; Ramsay C; Lazarowicz H; Allan A; Breckons M; Campbell K; Campbell L; Feber A; McDonald A; Norrie J; Orozco-Leal G; Rice S; Tandogdu Z; Taylor E; Wilson L; Vale L; MacLennan G; Hall E
Health Technol Assess; 2022 Oct; 26(40):1-144. PubMed ID: 36300825
[TBL] [Abstract][Full Text] [Related]
6. Photodynamic versus white light-guided treatment of non-muscle invasive bladder cancer: a study protocol for a randomised trial of clinical and cost-effectiveness.
Tandogdu Z; Lewis R; Duncan A; Penegar S; McDonald A; Vale L; Shen J; Kelly JD; Pickard R; N Dow J; Ramsay C; Mostafid H; Mariappan P; Nabi G; Creswell J; Lazarowicz H; McGrath J; Taylor E; Clark E; Maclennan G; Norrie J; Hall E; Heer R;
BMJ Open; 2019 Sep; 9(9):e022268. PubMed ID: 31481549
[TBL] [Abstract][Full Text] [Related]
7. The health economics of bladder cancer: a comprehensive review of the published literature.
Botteman MF; Pashos CL; Redaelli A; Laskin B; Hauser R
Pharmacoeconomics; 2003; 21(18):1315-30. PubMed ID: 14750899
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
[TBL] [Abstract][Full Text] [Related]
9. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
[TBL] [Abstract][Full Text] [Related]
10. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer.
Mowatt G; Zhu S; Kilonzo M; Boachie C; Fraser C; Griffiths TR; N'Dow J; Nabi G; Cook J; Vale L
Health Technol Assess; 2010 Jan; 14(4):1-331, iii-iv. PubMed ID: 20082749
[TBL] [Abstract][Full Text] [Related]
11. Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non-Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013.
Bree KK; Shan Y; Hensley PJ; Lobo N; Hu C; Tyler DS; Chamie K; Kamat AM; Williams SB
JAMA Netw Open; 2022 Mar; 5(3):e223050. PubMed ID: 35302627
[TBL] [Abstract][Full Text] [Related]
12. The economics of bladder cancer: costs and considerations of caring for this disease.
Svatek RS; Hollenbeck BK; Holmäng S; Lee R; Kim SP; Stenzl A; Lotan Y
Eur Urol; 2014 Aug; 66(2):253-62. PubMed ID: 24472711
[TBL] [Abstract][Full Text] [Related]
13. Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors.
Madeb R; Golijanin D; Noyes K; Fisher S; Stephenson JJ; Long SR; Knopf J; Lyman GH; Messing EM
Cancer; 2009 Jun; 115(12):2660-70. PubMed ID: 19455607
[TBL] [Abstract][Full Text] [Related]
14. Economic impact of tumor markers in bladder cancer surveillance.
Hong YM; Loughlin KR
Urology; 2008 Jan; 71(1):131-5. PubMed ID: 18242381
[TBL] [Abstract][Full Text] [Related]
15. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis.
Burger M; Zaak D; Stief CG; Filbeck T; Wieland WF; Roessler W; Denzinger S
Eur Urol; 2007 Jul; 52(1):142-7. PubMed ID: 17267099
[TBL] [Abstract][Full Text] [Related]
16. Early Photodynamic Diagnosis Cystoscopy After Bacillus Calmette-Guérin (BCG) Induction for High-Risk Nonmuscle Invasive Bladder Cancer Significantly Increased the Detection of BCG Refractory Tumors.
Morelli M; Baboudjian M; Vanacore D; Gondran-Tellier B; McManus R; Karsenty G; Lechevallier E; Montanari E; Boissier R
J Endourol; 2021 Dec; 35(12):1824-1828. PubMed ID: 34107773
[No Abstract] [Full Text] [Related]
17. Outpatient laser ablation of non-muscle-invasive bladder cancer: is it safe, tolerable and cost-effective?
Wong KA; Zisengwe G; Athanasiou T; O'Brien T; Thomas K
BJU Int; 2013 Sep; 112(5):561-7. PubMed ID: 23819486
[TBL] [Abstract][Full Text] [Related]
18. Improved diagnosis and long-term recurrence rate reduction for non-muscle-invasive bladder cancer patients undergoing fluorescent hexylaminolevulinate photodynamic diagnosis.
Drăgoescu PO; Tudorache Ş; Drocaş AI; Mitroi G; Pănuş A; Drăgoescu NAM; Meşină C; Mititelu CD; Stănculescu AD; Mohamed G; Tomescu PI
Rom J Morphol Embryol; 2017; 58(4):1279-1283. PubMed ID: 29556618
[TBL] [Abstract][Full Text] [Related]
19. The health economics of bladder cancer: an updated review of the published literature.
Yeung C; Dinh T; Lee J
Pharmacoeconomics; 2014 Nov; 32(11):1093-104. PubMed ID: 25056838
[TBL] [Abstract][Full Text] [Related]
20. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
Babjuk M; Burger M; Compérat EM; Gontero P; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Zigeuner R; Capoun O; Cohen D; Escrig JLD; Hernández V; Peyronnet B; Seisen T; Soukup V
Eur Urol; 2019 Nov; 76(5):639-657. PubMed ID: 31443960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
